RE:Independent Review Committee RequiredWhen I read their press releases it seems clear exactly what happened:
1. they launched smooth X for US market moving forward with device application, Feb 2023 FDA chaged back to a drug, that halted to momentum.
2. They moved forward with Canadian sales SmoothX and clinics did not want one product but 4-5 because of supply chain risk.
3. they are moving forward with remaining 4 products for Canada now. Its not like you can mix up a batch in a blender and start selling. each product has to follow GMP guidlines from formulation testing, quality control on ingredients, manufacturing processes and final products, this takes months, then saftey and perfarmance testing, takes months to do, then sales.
Managemnet has been crystal clear from my assesment of news. The CEO is also very approachable. The issue was the smoothX flop, and raising funds is not easy after a flop. Now look at what they are doing now, a new molecule, that opens them up to biotech financing, making all products at AVL, when that is completed they will begins sales. They are signing distribution agreements which is another tool for financing. I think Warrant Officer should put his name on the slate for director next AGM! But chnage name to Drill Sergeant A SS Kicker.